MET-233I
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Pfizer · Phase 1/2 · Completed · Enrollment 201
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.